Table 2.
Symptom score outcomes of included studies pre–post completed intervention
| Validated scales | ||||||
| Study | N* | Validated symptom scale | Time point pre–post data collected | Premean/median† (SD/range) | Post mean/median† (SD/range) | P value |
| Baxter et al, 201934 | 35 | ACQ | 12 months | 2.50 (1.32) | 2.05 (1.14) | 0.19 |
| ACT | 12 months | 13.21 (4.73) | 14.69 (4.94) | 0.28 | ||
| Haines et al,35 2016‡ | 16 | VCDQ | NR | 46† (20–60) | 38† (12–50)§ | 0.017 |
| Halevi-Katz,36 2019‡ | 12 | DI | 3 weeks | 2.00 (5.39) | 16.83 (3.31)§ | 0.0016 |
| Murry et al,38 2010‡ | 12¶ | RSI-7 | NR | NR | NR | 0.05** |
| Olley et al, 201340 | 4 | D12 | NR | 18.6 (7.8) | 6.3 (5.7) | NR |
| Non-Validated scales | ||||||
| 1) Polar question—‘Have your symptoms improved?’ | ||||||
| Study | N* | Time pre–post | % responding YES | P value | ||
| Krammer et al, 201733 | 25 | NR | 92 | NR | ||
| Marcinow et al, 201518 | 34 | NR | 100 (>2 sessions) 29 (1 session) | NR | ||
| Murry et al,38 2010‡ | 16 | NR | NR (asked separately for cough, throat clear and hoarseness) | <0.01 | ||
| 2) Ordinal severity scales | ||||||
| Study | N* | Time pre–post | Scale description; range†† | Pre measure(mean(SD) if applicable) | Post measure(mean(SD) if applicable) | P value |
| Hatzelis et al, 201237 | 1 | 12 months | Severity of symptoms; 1–5 | 5 | 1 | NR |
| Mathers-Schmidt and Brilla, 200522 | 1 | 16 weeks | Dyspnoea rating scale; 1–3 | 2.4 | 1.3 | NR |
| Nacci et al, 2011 ‡39 | 10 | 24 months (received three intervention cycles) | Severity of symptoms; 1–10 | 9.2 | 6.2 | p<0.01 |
| 10 | 24 months (received eight intervention cycles) | 9.3 | 2.5 | p<0.01 | ||
| Warnes et al, 200544 | 1 | NR | Severity adaptive functioning; 1–6 | 5 | 0 | NR |
| 3) Symptom quantification | ||||||
| Study | N* | Time pre–post | Description | Pre measure(mean(SD) if applicable) | Post measure(mean(SD) if applicable) | P value |
| Mathers-Schmidt and Brilla, 200518 | 1 | 16 weeks | Time to symptom onset | 23 s | 30 s | NR |
| Pargeter & Mansur, 201641 | 249 | NR | Frequency of patient reported daily attacks | 72% | 10% | NR |
| 4) Symptom questionnaire | ||||||
| Study | N* | Time pre–post | Description | Pre measure (mean(SD) if applicable) | Post measure (mean(SD) if applicable) | P value |
| Pargeter & Mansur,41 2016‡ | 249 | NR | In-house ILO symptom questionnaire; high score indicating poor control | 16.57 (3.96) | 7.75 (4.82) | <0.001 |
| 5) Multichoice question | ||||||
| Study | N* | Time pre–post | Description | Pre measure (mean (SD) if applicable) | Post measure (mean (SD) if applicable) | P value |
| Shin et al, 201843 | 46 | NR | Have symptoms a) not improved b) improved c) worsened | NA | 50% improve 22% worsen | NR |
*Number of participants.
†Median.
‡Studies reported statistically significant improvements pre–post intervention.
§Improved by the reported clinically meaningful response reported DI Dyspnoea Index Questionnaire; RSI Reflux Symptom Index item 7.
¶Only reported in 12/16 participants.
**Mean difference in score 3.76, no pre–post scores reported; D12 Dysponea12.
††Highest value most impairment.
ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; NR, Not reported; VCDQ, Vocal Cord Dysfunction Questionnaire.